Premium
Induction of tumor regression by intratumoral STING agonists combined with anti–programmed death‐L1 blocking antibody in a preclinical squamous cell carcinoma model
Author(s) -
Gadkaree Shekhar K.,
Fu Juan,
Sen Rupashree,
Korrer Michael J.,
Allen Clint,
Kim Young J.
Publication year - 2017
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24704
Subject(s) - head and neck squamous cell carcinoma , immunotherapy , cancer research , medicine , immunogenic cell death , programmed cell death , melanoma , splenocyte , tumor microenvironment , agonist , antibody , cd8 , cancer , apoptosis , immunology , chemistry , immune system , receptor , head and neck cancer , biochemistry
Background Cyclic dinucleotides (CDNs) are bacterial intracellular messengers that have demonstrated antitumor activity in melanoma and breast tumors, although their role in immunotherapy of head and neck squamous cell cancers (HNSCCs) has not been well investigated. Methods We measured primary tumor growth rates, mechanism of antitumor activity, and efficacy of programmed death‐L1 blockade combinatorial therapy in SCCFVII tumor‐bearing C3H/HeOUJ mice undergoing intratumoral injections with RR‐cyclic‐di‐guanine (synthetic CDG), CDG (natural cyclic‐di‐guanine), R848 (TLR 7/8 agonist), or phosphate buffered saline (PBS, control). Results Intratumoral CDN treatment groups showed decreased tumor size and enhanced splenocyte Th1 response when compared to the PBS treatment control group ( p < .05). The RR‐CDG tumor microenvironment showed upregulated interferon (IFN)‐γ+CD8+ and programmed death‐L1. Combining programmed death‐L1 blocking antibody with RR‐CDG induced regression of established tumors. Conclusion This study demonstrates the antitumor effects of CDNs in a HNSCC cell line. These preclinical data strongly support the future clinical development of intratumoral CDN in patients with HNSCC. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1086–1094, 2017